# Bisphosphonate vs Denosumab: Which Is Better for Preventing Osteoporotic Fractures?

Lily Armstrong · September 5, 2026

> Direct Answer: Two Different Tools for the Same Job Bisphosphonates and denosumab both reduce the risk of osteoporotic fractures, but they are not...

## Direct Answer: Two Different Tools for the Same Job

Bisphosphonates and denosumab both reduce the risk of osteoporotic fractures, but they are not interchangeable. Bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid are taken orally (weekly or monthly) or given as an annual intravenous infusion, and they bind to bone where they suppress osteoclast activity for months to years. Denosumab (Prolia) is a monoclonal antibody injected under the skin every six months that blocks RANKL, a protein required for osteoclast formation. The 2009 FREEDOM trial published in The New England Journal of Medicine showed denosumab cut new vertebral fractures by 68%, hip fractures by 40%, and non-vertebral fractures by 20% over three years in postmenopausal women with osteoporosis. Oral bisphosphonates in landmark trials (FIT, HORIZON) typically reduce vertebral fracture risk by 40-70% and hip fracture risk by 20-40% over similar durations. Head-to-head DAPS and DECIDE trials found denosumab produced slightly larger BMD gains than alendronate, but no trial has shown a definitive mortality or fracture superiority of one class over the other.

**Also worth reading:** [What are the official denosumab transition protocol guidelines for patients switching from or to bisphosphonate therapy?](https://healtho.io/knowledge/what_are_the_official_denosumab_transition_protocol_guidelines_for_patients_switching_from_or_to_bisphosphonate_therapy.php) · [What are the best COPD meal plan ideas for managing breathlessness and preventing weight loss?](https://healtho.io/knowledge/what_are_the_best_copd_meal_plan_ideas_for_managing_breathlessness_and_preventing_weight_loss.php) · [What is the denosumab withdrawal fracture risk and how should patients manage it after stopping treatment?](https://healtho.io/knowledge/what_is_the_denosumab_withdrawal_fracture_risk_and_how_should_patients_manage_it_after_stopping_treatment.php)

## How Each Drug Actually Works

Bisphosphonates are synthetic analogs of pyrophosphate that adhere to hydroxyapatite in bone. When osteoclasts resorb bone containing bisphosphonate, the drug disrupts their cytoskeleton and induces apoptosis. This produces a durable reduction in bone turnover that persists for years because the drug remains embedded in the skeleton; alendronate, for example, has a skeletal half-life estimated at more than 10 years. The 2010 NEJM paper on atypical femur fractures demonstrated that long-term bisphosphonate use (typically beyond 3-5 years) produces a measurable but small rise in AFF risk.

Denosumab is a fully human IgG2 monoclonal antibody that binds RANKL and prevents it from activating the RANK receptor on osteoclast precursors. Unlike bisphosphonates, denosumab does not deposit in bone. Its effect on bone resorption wanes within 6-9 months of the last injection, which is why missed or delayed doses cause rapid bone loss. A 2018 paper in The Journal of Clinical Endocrinology & Metabolism reported that discontinuation without follow-up bisphosphonate therapy led to 5-11% loss of lumbar spine BMD within 12 months and rebound vertebral fracture rates as high as 7.1 per 100 patient-years.

## Practical Steps for Choosing Between Them

The 2020 AACE/ACE and 2024 updated Endocrine Society guidelines both endorse oral bisphosphonates as first-line therapy for most postmenopausal women with osteoporotic BMD (T-score ≤ -2.5) or fragility fractures. Denosumab is generally reserved for patients with impaired renal function (eGFR below 30-35 mL/min/1.73 m²), gastrointestinal intolerance to oral bisphosphonates, or those at very high fracture risk (T-score ≤ -3.0, recent hip or vertebral fracture, or multiple prior fractures). The AAFP Common Questions document emphasizes shared decision-making, baseline dual-energy X-ray absorptiometry (DXA), and a 10-year FRAX score before starting either agent. Calcium intake of 1,000-1,200 mg/day and vitamin D of 800-1,000 IU/day should accompany treatment regardless of drug choice. For those unable to sit upright for 30-60 minutes after dosing, oral bisphosphonates are contraindicated and IV zoledronate or denosumab is preferred.

## Comparison Table: Side-by-Side at a Glance

| Feature | Oral Bisphosphonate (alendronate) | Denosumab (Prolia) |
| --- | --- | --- |
| Dosing | Weekly oral or yearly IV (zoledronate) | Subcutaneous injection every 6 months |
| Onset of effect | 6-12 months for fracture reduction | 6-12 months for fracture reduction |
| Reversibility | Effect persists 1-5 years after stop | Reverses within 6-9 months of last dose |
| Vertebral fracture reduction (3 yr) | ~40-50% | ~68% |
| Hip fracture reduction (3 yr) | ~20-30% | ~40% |
| BMD gain at lumbar spine (24 mo) | +5-7% | +8-10% |
| Common adverse effects | GI upset, esophageal irritation | Injection-site reactions, myalgia |
| Rare serious risks | Atypical femur fracture (long-term), ONJ | Rebound vertebral fractures after stop, ONJ |
| Renal limits | Avoid if eGFR

Canonical: https://healtho.io/knowledge/bisphosphonate_vs_denosumab_which_is_better_for_preventing_osteoporotic_fractures.php
Markdown: https://healtho.io/knowledge/bisphosphonate_vs_denosumab_which_is_better_for_preventing_osteoporotic_fractures.php/index.md